Abstract

The present disclosure describes the synthesis, characterization, and purification of functionalized aromatic phosphonic acids (FAPAs) for use as hole extraction materials in perovskite solar cells and display devices. Embodiments of the present disclosure provide a method to prepare FAPAs with varying dipoles that can significantly improve the electronic properties of electrode materials used in displays and photovoltaic devices. The FAPA may be tuned for specific active layers. Aspects of the disclosure include phosphonic acid molecules that enhance bonding at the perovskite/substrate interface to create a strong hole extraction polymer retaining high efficiency and improving ultraviolet stability of perovskite solar cells by suppressing ion migration at the embedded interface.

IPC Classes  ?

• H10K 30/86 - Layers having high hole mobility, e.g. hole-transporting layers or electron-blocking layers
• C07F 9/572 - Five-membered rings
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 50/15 - Hole transporting layers
• H10K 85/10 - Organic polymers or oligomers
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• H10K 85/60 - Organic compounds having low molecular weight

Abstract

The disclosure is directed to quinoxaline containing compounds of Formula: (I) that bind to a target RNA molecule, such as a TPP riboswitch, compositions comprising the compounds, and methods of making and using the same.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 487/08 - Bridged systems
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
• A61P 35/00 - Antineoplastic agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61P 7/04 - AntihaemorrhagicsProcoagulantsHaemostatic agentsAntifibrinolytic agents
• A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Abstract

This invention describes compositions and methods for producing chimeric antigen receptor (CAR)-expressing immune cells that have stem cell-like features and have enhanced antitumor functionality. Also described herein are methods of using the same such as in the treatment of cancer.

IPC Classes  ?

• A61K 38/45 - Transferases (2)
• C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
• A61K 38/43 - EnzymesProenzymesDerivatives thereof

Abstract

Described herein are NO-releasing chondroitin sulfate (CS) polymers, methods for preparing the polymers, and their use for the treatment of various medical conditions, such as infected wounds.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups Derivatives thereof
• A61K 31/726 - Glycosaminoglycans, i.e. mucopolysaccharides
• A61P 31/02 - Local antiseptics

Abstract

A delivery system for local drug delivery to a target site of internal body tissue is provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A reservoir is configured to be disposed such that the reservoir is capable of interacting with the localized electric field. The reservoir is configured to carry a cargo capable of being delivered to the target site when exposed to the localized electric field. Associated methods are also provided.

IPC Classes  ?

• A61N 1/30 - Apparatus for iontophoresis or cataphoresis
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/14 - Probes or electrodes therefor
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61N 1/00 - ElectrotherapyCircuits therefor
• A61N 1/04 - Electrodes
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/18 - Applying electric currents by contact electrodes
• A61N 1/20 - Applying electric currents by contact electrodes continuous direct currents
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61N 1/36 - Applying electric currents by contact electrodes alternating or intermittent currents for stimulation, e.g. heart pace-makers
• A61N 5/00 - Radiation therapy

Abstract

Positron emission tomography and magnetic resonance imaging are among the most widely used modalities, requiring isotopic labeling of bioactive molecules to generate the desired imaging probes. This method was applied to a wide range of aliphatic carboxylic acids, including complex and functionalized drug molecules, amino acids and short peptides. For non-stabilized radicals derived from benzylic and non-benzylic carboxylic acids, a copper co-catalyst was introduced to obtain the labeled nitriles, whereas metal-free conditions were applied to nitrogen-stabilized radical derived from a-amino acids and peptides to form the radiolabeled a-amino nitriles. These radiolabeled nitriles were then easily converted back to radiolabeled carboxylic acids.

IPC Classes  ?

• A61K 47/00 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient
• A61K 51/02 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier
• A61K 51/08 - Peptides, e.g. proteins
• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• C07B 43/08 - Formation or introduction of functional groups containing nitrogen of cyano groups
• C07C 253/00 - Preparation of carboxylic acid nitriles
• C07C 269/06 - Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
• C07J 1/00 - Normal steroids containing carbon, hydrogen, halogen, or oxygen, not substituted in position 17 beta by a carbon atom, e.g. oestrane, androstane
• C07K 5/08 - Tripeptides
• C07K 5/06 - Dipeptides
• C07D 337/14 - [b, f]-condensed

Abstract

In one aspect, composite compositions are described herein for delivery of various bioactive compositions. In some embodiments, a composite composition comprises a metal-organic coordination polymer matrix, and one or more bioactive compositions carried by the metal-organic coordination polymer matrix, wherein the metal-organic coordination polymer matrix comprises polymeric chains including a repeating unit of formula I.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/02 - Inorganic compounds
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein

Abstract

Disclosed herein is a G protein-coupled receptor (GPCR) assay platform comprised of two complementary systems that equate dynamic intermolecular interactions between a receptor and transducer with more complex stimulus-response cascades in living cells. In the disclosed in vitro ADSoRB method, the forced dissociation of transducers like G protein heterotrimers from receptors alters receptor conformations and ligand interactions to simulate pathway activation in a cell. In the disclosed TRUPATH method, measuring the extent of engineered G protein heterotrimer complex dissociation provides single transducer resolution in a cell.

IPC Classes  ?

• G01N 33/566 - ImmunoassayBiospecific binding assayMaterials therefor using specific carrier or receptor proteins as ligand binding reagent
• C12N 15/62 - DNA sequences coding for fusion proteins

Abstract

A system may include a wearable device capable of collecting visual data, motion data, or a combination thereof. A system may include a processor for analyzing the data to assess physical functioning.

IPC Classes  ?

• A61B 5/11 - Measuring movement of the entire body or parts thereof, e.g. head or hand tremor or mobility of a limb
• A61B 5/024 - Measuring pulse rate or heart rate
• G06N 20/00 - Machine learning
• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indicesICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons

Abstract

The present disclosure relates materials and methods related to the removal of per-and polyfluorinated alkyl compounds from water. More specifically, the materials disclosed herein are functionalized resins made from crosslinked polymers containing a cationic headgroup bound to the resin, which can be used to remove the per-and polyfluorinated alkyl compounds from water.

IPC Classes  ?

• C08F 8/30 - Introducing nitrogen atoms or nitrogen-containing groups
• C08F 212/08 - Styrene
• C08F 212/36 - Divinylbenzene
• C08F 212/14 - Monomers containing only one unsaturated aliphatic radical containing one ring substituted by hetero atoms or groups containing hetero atoms
• C02F 1/28 - Treatment of water, waste water, or sewage by sorption
• B01J 20/26 - Synthetic macromolecular compounds
• C02F 101/36 - Organic compounds containing halogen

Abstract

The disclosure relates to radiolabeled aromatic electrophile prosthetic groups, which can be used to prepare bioactive ligands containing PET, SPECT, alpha- or beta-emitting radioisotopes, and their use in treating and/or imaging cancer.

IPC Classes  ?

• C07B 31/00 - Reduction in general
• C07B 59/00 - Introduction of isotopes of elements into organic compounds
• A61K 51/04 - Organic compounds
• A61K 51/08 - Peptides, e.g. proteins
• C07C 217/58 - Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by singly-bound oxygen atoms with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
• C07C 235/50 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by nitrogen atoms not being part of nitro or nitroso groups
• C07C 247/04 - Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being saturated
• C07C 247/10 - Compounds containing azido groups with azido groups bound to acyclic carbon atoms of a carbon skeleton being unsaturated and containing rings
• C07C 271/20 - Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by nitrogen atoms not being part of nitro or nitroso groups
• C07C 271/64 - Y being a hydrogen or a carbon atom, e.g. benzoylcarbamates
• C07D 207/452 - Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom

Abstract

A method for producing a microfluidic device, the method comprising: producing a first housing portion and a second housing portion; securing the second housing portion to the first housing portion; enclosing a three-dimensional biomaterial structure between the first housing portion and the second housing portion; and forming one or more channel within the biomaterial structure, the one or more channel being configured to model a hollow tissue structure; wherein the biomaterial structure and the one or more channel are configured for modeling a cellular transport barrier in a flow environment.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means

Abstract

Described herein are non-stoichiometric perovskite ink solutions, comprising: a first composition of formula FA1-xCsxBX3; a second composition of CsX, FAX, REX3, or REX2; and one or more solvents; wherein x, X, RE, and B are as defined herein. Methods for preparing polycrystalline perovskite films using the non-stoichiometric ink solutions and the use of the films in large-size solar modules are additionally described.

IPC Classes  ?

• C09D 11/52 - Electrically conductive inks
• C09D 11/033 - Printing inks characterised by features other than the chemical nature of the binder characterised by the solvent
• C09D 11/037 - Printing inks characterised by features other than the chemical nature of the binder characterised by the pigment
• H01G 9/20 - Light-sensitive devices
• H10K 30/20 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising organic-organic junctions, e.g. donor-acceptor junctions
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3

Abstract

The present disclosure pertains to methods of enhancing abiotic stress resistance in a plant or seed by altering one or more KMD family of genes of the plant or seed. The altered KMD family of genes includes, without limitation, KMD1, KMD2, KMD3, KMD4, a gene encoding a protein with at least 40% amino-acid sequence identity with any one of KMD 1-4, or combinations thereof. The present disclosure also pertains to plants or seeds that include one or more of the aforementioned altered KMD family of genes. The present disclosure also pertains to methods of growing a plant or a seed in a field by applying a plant or seed that includes one or more of the aforementioned altered KMD family of genes to the field.

IPC Classes  ?

• C12N 15/82 - Vectors or expression systems specially adapted for eukaryotic hosts for plant cells
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)
• C12N 15/29 - Genes encoding plant proteins, e.g. thaumatin

Abstract

The invention relates to a new NTSR1 ligand, SR-CP-05, for targeted imaging and therapy. The invention also relates to a neurotensin receptor (NTSR1)-specific ligand that is suitable for radiolabeling and comprises a neurotensin ligand, a linker, and a chelator for binding a radioisotope. In some embodiments, a composition comprising the NTSR1-specific ligand is used for imaging, diagnosing, and/or guidance of treatment of a NTSR1-positive cancer.

IPC Classes  ?

• A61K 51/04 - Organic compounds

Abstract

A method and system for combination therapy utilizing local drug delivery and radiotherapy at a target site of body tissue are provided. The delivery system comprises a source electrode adapted to be positioned proximate to a target site of internal body tissue. A counter electrode is in electrical communication with the source electrode, and is configured to cooperate with the source electrode to form a localized electric field proximate to the target site. A cargo may be delivered to the target site when exposed to the localized electric field. Radiotherapy is applied to the target site in combination with the local drug delivery.

IPC Classes  ?

• A61N 5/10 - X-ray therapyGamma-ray therapyParticle-irradiation therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61M 37/00 - Other apparatus for introducing media into the bodyPercutany, i.e. introducing medicines into the body by diffusion through the skin
• A61N 1/04 - Electrodes
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents

Abstract

The subject matter described herein is directed to methods of preparing linear and brush polymers with functional backbones and the polymers prepared therefrom. The methods are termed RAFT step-growth polymerizations and can prepare unique polymers by using a step-growth mechanism to insert multiple functionalities into the polymer backbone. The methods include facile syntheses to obtain tunable polymers, including a two-step process to obtain tunable bottlebrush polymers.

IPC Classes  ?

• C08F 120/38 - Esters containing sulfur
• C08F 122/40 - Imides, e.g. cyclic imides

Abstract

Disclosed herein are methods for rapidly screening polymer nanoparticles by exposing a cell to the polymer nanoparticle, the polymer nanoparticle comprising a detectably labeled mRNA, the mRNA encoding a detectable protein; and sorting the exposed cell by the presence or absence of a signal from the detectably labeled mRNA and the detectable protein via flow cytometry; and evaluating the polymer nanoparticle for its ability to deliver the mRNA to the cell and express the protein based on the presence or absence of the signals. Novel polymer nanoparticles, in particular, lipid nanoparticles are also provided herein.

IPC Classes  ?

• G01N 15/14 - Optical investigation techniques, e.g. flow cytometry
• A61K 9/1271 - Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
• C12Q 1/6818 - Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
• G01N 21/64 - FluorescencePhosphorescence
• A61K 38/13 - Cyclosporins
• C01B 25/32 - Phosphates of magnesium, calcium, strontium, or barium
• C07C 331/16 - Isothiocyanates
• C09B 23/04 - Methine or polymethine dyes, e.g. cyanine dyes characterised by the methine chain containing an odd number of CH groups one CH group, e.g. cyanines, isocyanines, pseudocyanines
• C12P 13/10 - CitrullineArginineOrnithine

Abstract

This invention relates to feedback-enabled synthetic genes, polynucleotide target cassettes, vectors, and pharmaceutical compositions for the purpose of providing transgene expression in target tissues that is capable of endogenous regulation for treating disorders such as dose-sensitive intellectual ability disorders, as well as methods of making and methods of using the same.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Goods & Services

Entertainment and educational services, namely, providing courses of instruction at the university level; arranging and conducting athletic competitions, athletic events, athletic tournaments, and athletic exhibitions

Goods & Services

Jerseys being clothing; T-shirts; Headwear

Goods & Services

Jerseys being clothing; T-shirts; Sweatshirts; Footwear; Headwear

Abstract

The invention relates to commercially viable methods for producing biologically active vitamin K dependent proteins, particularly Factor IX. Factor IX is produced at a level of at least about 15 mg/L and is at least 25% biologically active. The method relies upon co-expression of one or more of paired basic amino acid converting enzyme (PACE), vitamin K dependent epoxide reductase (VKOR) and vitamin K dependent γ-glutamyl carboxylase (VKGC) at a preferred ratio so that the vitamin K dependent protein is efficiently produced and processed by a recombinant cell.

IPC Classes  ?

• C12P 21/00 - Preparation of peptides or proteins
• C12N 9/04 - Oxidoreductases (1.), e.g. luciferase acting on CHOH groups as donors, e.g. glucose oxidase, lactate dehydrogenase (1.1)
• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• C12N 9/74 - Thrombin
• C12N 9/88 - Lyases (4.)

Abstract

Disclosed herein are compositions and methods for modifying B cells. Particles such as hydrophobic microparticles or nanoparticles are described for use in delivering agents to B cells, generating regulatory B cells and inducing IL-10 production by B cells. Particles, or B cells bound to the same, are also provided for use in methods for treating an inflammatory or autoimmune disease or condition, inducing immune tolerance, and sustained delivery of an agent to a subject.

IPC Classes  ?

• A61K 40/13 - B-cells
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/51 - Nanocapsules
• A61P 37/00 - Drugs for immunological or allergic disorders
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

This invention relates to a modified Carboxyl Terminus of Heat Shock Cognate 70-interacting protein (CHIP) or functional fragment thereof wherein the modified CHIP or functional fragment thereof comprises at least two amino acid modifications that reduce the activity of a U-Box domain and a tetratricopeptide repeat (TPR) domain. The modified CHIP or functional fragment thereof may be used to treat neurological diseases and diseases associated with tau protein aggregates and tau protein phosphorylation, such as neurodegenerative diseases, neuroinflammation, traumatic brain injury (TBI), and cerebrovascular disease (CVD).

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The present invention is directed to a method of making a live cell construct or a support, comprising: (a) providing a non-cellular organic polymer support having a top surface, a bottom surface, and an intermediate portion there between, and (b) contacting a cross-linking agent to one surface of said support for a time sufficient to generate a gradient of cross-linking of said polymer in said intermediate portion. Also provided are live cell constructs, supports, and methods of use of the supports and live cell constructs.

IPC Classes  ?

• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/42 - Apparatus for the treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic wave
• C12N 5/00 - Undifferentiated human, animal or plant cells, e.g. cell linesTissuesCultivation or maintenance thereofCulture media therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The subject matter described herein is directed to degraders having the formula: and pharmaceutically acceptable salts thereof, and compositions thereof, including pharmaceutical compositions, and methods of treating disorders associated with TAM receptor tyrosine kinases and/or TYRO3.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 47/55 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
• A61P 35/00 - Antineoplastic agents
• A61P 31/12 - Antivirals
• A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• A61P 43/00 - Drugs for specific purposes, not provided for in groups

Abstract

Methods of treating a tumor in a subject comprising administering to the subject an amount of a RASMULTI inhibitor and an amount of a TEAD inhibitor, effective to treat a tumor, and methods of treating a tumor resistant to a RASMULTI inhibitor therapy comprising administering to a tumor so-identified an amount of a RASMULTI inhibitor and an amount of a TEAD inhibitor, effective to treat a tumor resistant to a RASMULTI inhibitor therapy.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method for synthesizing magnetic resonance (MR) images with a plurality of contrasts includes generating, using a processor device, a contrast dictionary using a physics-based signal model, retrieving, using the processor device, a plurality of quantitative tissue maps for an anatomy of interest for one or more subjects, synthesizing, using the processor device, a plurality of MR images with a plurality of contrasts using the plurality of quantitative tissue maps and the contrast dictionary, and storing, using the processor device, the plurality of synthesized MR images in a data storage.

IPC Classes  ?

• G01R 33/56 - Image enhancement or correction, e.g. subtraction or averaging techniques
• G06T 7/00 - Image analysis

Abstract

The subject matter disclosed herein is directed to nitric oxide releasing particles comprising a mesoporous silica network. Also disclosed are compositions comprising one or more nitric-oxide releasing particles and a polymer. In one aspect, the particles are admixed with the polymer. The compositions exhibit high payloads of nitric oxide release without particle leaching or the need for extremely cold storage conditions.

IPC Classes  ?

• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61K 9/14 - Particulate form, e.g. powders
• A61K 33/00 - Medicinal preparations containing inorganic active ingredients

Abstract

Disclosed are improved catalytic carbonylation methods. In general, the methods are suitable for carbonylating a variety of esters in the presence of carbon monoxide or a source thereof and a catalyst system comprising a transition metal-carbene complex; or a neutral carbene or salt thereof together with a transition metal compound; and a halide source for use as a halide promoter.

IPC Classes  ?

• C07C 51/56 - Preparation of carboxylic acid anhydrides from organic acids, their salts, or their esters
• B01J 31/22 - Organic complexes

Abstract

Contrast agents for blood pool and functional liver imaging are described. For example, the contrast agents can be lipid nanoemulsions that include nanoparticles containing an oil component, a surfactant component, and one or more imaging moieties. The surfactant and oil components can be derived from biocompatible molecules, such as oleic acid. The contrast agents can provide efficient contrast for x-ray computed tomography (CT) with minimal toxicity and have higher iodine payloads compared to other liposomal and micellular agents. Alternatively or additionally, the agents can be loaded with therapeutic agents, e.g., for treatment of liver-based primary and metastatic tumors.

IPC Classes  ?

• A61K 49/06 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations
• A61K 49/18 - Nuclear magnetic resonance [NMR] contrast preparationsMagnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
• A61P 35/00 - Antineoplastic agents

Abstract

An extracellular vesicle based therapeutic compound for treating tumors and cancers. The extracellular vesicle based therapeutics use exosomes that are transdifferentiation-derived induced neural stem cells (Exo-iNSCs) that produce an extracellular vesicle having a tumoricidal gene product or an anti-cancer molecule withing the extracellular vesicle. The therapeutic agent is present in a lumen of the extracellular vesicle or is distributed across a membrane surface of the extracellular vesicle. Methods of using the extracellular vesicle based therapeutic compounds are effective in treating tumors and cancers.

IPC Classes  ?

• C12N 5/0797 - Stem cellsProgenitor cells
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• C12N 15/86 - Viral vectors
• A61P 35/00 - Antineoplastic agents

Abstract

Described herein are perovskite ink solutions comprising a composition of Formula I (APbI3-zBrz), a tribromide salt, and a solvent, wherein z is defined herein. Further described are perovskite films prepared using the ink solutions, methods for preparing the perovskite films, and use of the films in wide band gap single junction and tandem solar cells. As shown herein, solar cells fabricated using the perovskite films prepared from ink solutions comprising a tribromide salt achieve enhanced efficiency compared to solar cells comprising a perovskite film prepared without the tribromide salt.

IPC Classes  ?

• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3
• C09D 11/033 - Printing inks characterised by features other than the chemical nature of the binder characterised by the solvent
• C09D 11/037 - Printing inks characterised by features other than the chemical nature of the binder characterised by the pigment
• C09D 11/52 - Electrically conductive inks
• H10F 77/70 - Surface textures, e.g. pyramid structures
• H10K 30/10 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising heterojunctions between organic semiconductors and inorganic semiconductors
• H10K 30/57 - Photovoltaic [PV] devices comprising multiple junctions, e.g. tandem PV cells
• H10K 85/10 - Organic polymers or oligomers
• H10K 85/20 - Carbon compounds, e.g. carbon nanotubes or fullerenes
• H10K 85/60 - Organic compounds having low molecular weight

Abstract

Methods of treating a tumor in a subject comprising administering to the subject an amount of a RASMULTIinhibitor and an amount of a TEAD inhibitor, effective to treat a tumor, and methods of treating a tumor resistant to a RASMULTIinhibitor therapy comprising administering to a tumor so-identified an amount of a RASMULTIinhibitor and an amount of a TEAD inhibitor, effective to treat a tumor resistant to a RASMULTI inhibitor therapy.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/33 - Heterocyclic compounds

Abstract

The present disclosure provides novel training systems and methods for recurrent neural network models. One such method comprises obtaining a first sequence of sparse input data as training data; augmenting the first sequence of sparse input data by zero-filling missing input points; training the recurrent neural network model using the augmented sequence of sparse input data to obtain a trained recurrent neural network model, and applying new data as an input to the trained recurrent neural network model, wherein the new data comprises a second sequence of sparse input data to obtain a corresponding output data sequence.

IPC Classes  ?

• G06V 10/774 - Generating sets of training patternsBootstrap methods, e.g. bagging or boosting
• G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks

Abstract

Described herein are glycosaminoglycan articles (e.g., test strips, detection systems, and binding pairs) along with methods of making and using the same.

IPC Classes  ?

• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
• G01N 33/543 - ImmunoassayBiospecific binding assayMaterials therefor with an insoluble carrier for immobilising immunochemicals

Abstract

A decannulation detection system includes a dressing, a tube assembly, and a controller. The dressing is applied over a wound or incision site and includes a first electric circuit portion. The tube assembly is positioned in contact with the dressing and includes a second electric circuit portion. When the tube assembly is in contact with the dressing, the first and second electrical circuit portions form a complete electric circuit. The controller is electrically connected to the complete electric circuit and is used to monitor electrical continuity in the complete electric circuit. When the controller detects an electrical discontinuity in the complete electric circuit, the controller triggers an alert regarding the possible occurrence of a decannulation event.

IPC Classes  ?

• A61M 16/04 - Tracheal tubes
• A61F 13/00 - Bandages or dressingsAbsorbent pads
• A61M 16/00 - Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators Tracheal tubes

Abstract

The present invention provides a method of diagnosing endometriosis and/or infertility in a subject, comprising: a) obtaining a sample from the subject; b) detecting a level of expression of a SIRT1 gene and/or protein in the sample; c) detecting a level of expression of a BCL6 gene and/or protein in the sample; d) comparing the level of expression detected in (b) with the level of expression of a SIRT1 gene and/or protein in a sample obtained from a control subject or a population of control subjects; e) comparing the level of expression detected in (c) with the level of expression of a BCL6 gene and/or protein in a sample obtained from a control subject or a population of control subjects; and f) diagnosing the subject as having infertility when the subject has a level of expression of the SIRT1 gene and/or protein greater than the level of expression of the SIRT1 gene and/or protein of the control subject or population of control subjects and also has a level of expression of the BCL6 gene and/or protein that is greater than the level of expression of the BCL6 gene and/or protein of the control subject or population of control subjects.

IPC Classes  ?

• G16B 40/10 - Signal processing, e.g. from mass spectrometry [MS] or from PCR
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present subject matter relates to devices, systems, and methods for use in physical therapy of the pelvic floor and/or for treating pelvic floor dysfunction (PFD) and pelvic pain. The devices, systems, and methods can provide a pelvic floor physical therapy device that includes a handle portion configured to be gripped by a user; a body portion extending from the handle portion; and one or more sensors integrated within the body portion. The one or more sensors can be configured to collect sensor data regarding a position of the pelvic floor physical therapy device with respect to a pelvic floor location or pelvic floor muscle of a user. Visual or auditory feedback can be provided to the user regarding the position of the pelvic floor physical therapy device with respect to the pelvic floor location or pelvic floor muscle to guide a physical therapy treatment session.

IPC Classes  ?

• A63B 23/20 - Exercising apparatus specially adapted for particular parts of the body for vaginal muscles
• A63B 21/00 - Exercising apparatus for developing or strengthening the muscles or joints of the body by working against a counterforce, with or without measuring devices
• A63B 71/06 - Indicating or scoring devices for games or players

Abstract

According to some embodiments, a patch for organ and/or tissue application is provided which comprises a biocompatible polymeric material having an auxetic architecture and further matching a stiffness ratio and/or Poisson's ratio of an organ or tissue to which the patch is applied. According to some further embodiments, biocompatible patches and methods of making the same are provided comprising providing a layer of hydrogel and forming an auxetic architecture by selectively crosslinking areas of the hydrogel via exposure to light, wherein the auxetic architecture is selected to match a stiffness ratio and Poisson's ratio of an organ to which the biocompatible patch is applied.

IPC Classes  ?

• A61L 27/52 - Hydrogels or hydrocolloids
• A61L 27/22 - Polypeptides or derivatives thereof
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials

Abstract

Disclosed herein is an adeno-associated virus (AAV) particle comprising a surface-bound peptide that enhances transduction of cells across the blood-brain barrier (BBB). Also disclosed herein is a modified AAV capsid protein comprising an insertion of a polypeptide that enhances transduction of cells across the BBB, and an AAV particle comprising the modified AAV capsid protein. Specific peptides are provided. Pharmaceutical formulations and method of administering/delivering a nucleic acid to a cell of the brain and/or central nervous system are also disclosed.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

This invention relates to methods for inhibiting or reducing the risk of thrombosis or reducing the size and number of thrombi without compromising hemostasis using a nonpolymerizable fibrinogen that is insensitive to thrombin cleavage. Methods and compositions for reducing a required dose or complementing the effect of an antithrombotic agent in the treatment of thrombosis are also provided.

IPC Classes  ?

• A61K 38/36 - Blood coagulation or fibrinolysis factors
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 7/02 - Antithrombotic agentsAnticoagulantsPlatelet aggregation inhibitors
• C07K 14/75 - Fibrinogen

Abstract

Disclosed are methods of treating drug-induced liver injury using synthetic heparan sulfate oligosaccharides having 12, 14, or 16 saccharide residues. For example, the drug-induced liver injury can be acetaminophen (APAP)-induced acute liver failure. Also disclosed are methods of treating sepsis using synthetic heparan sulfate oligosaccharides having 12, 14, 16, or 18 saccharide residues, as well as select 12-, 14- and 16-mer oligosaccharides and their pharmaceutical compositions.

IPC Classes  ?

• C07H 15/02 - Acyclic radicals, not substituted by cyclic structures
• C07H 17/04 - Heterocyclic radicals containing only oxygen as ring hetero atoms
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems

Abstract

Described herein are compositions and methods for reducing or preventing a hypersensitivity reaction in a subject. In particular, described are compositions and methods for reducing or prophylactically preventing hypersensitivity reactions in a subject otherwise due to a response to the PEG portion of PEGylated compounds and substrates, including PEGylated drugs and vaccines.

IPC Classes  ?

• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 37/00 - Drugs for immunological or allergic disorders

Abstract

This invention relates to mature flavivirus particles and methods of making and using the same. This invention further relates to flavivirus E glycoproteins, nucleic acids encoding the same, as well as particles, populations, and compositions comprising the same. Also disclosed are methods of making and using the E glycoproteins of the invention.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 39/12 - Viral antigens
• A61P 37/04 - Immunostimulants

Abstract

The present invention provides AAV capsid proteins comprising a modification in the amino acid sequence and virus capsids and virus vectors comprising the modified AAV capsid protein. The invention also provides methods of administering the virus vectors and virus capsids of the invention to a cell or to a subject in vivo.

IPC Classes  ?

• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 27/00 - Drugs for disorders of the senses
• A61P 27/02 - Ophthalmic agents
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12N 15/86 - Viral vectors

Abstract

Disclosed herein are methods of treating melanoma, such as, e.g., stage III/IV cutaneous or mucosal melanoma, in a subject in need thereof, comprising administering a therapeutically effective amount of denosumab to the subject and optionally co-administering a therapeutically effective amount of a PD-1 inhibitor to the subject; uses of denosumab or a PD-1 inhibitor in the manufacture of a medicament adapted for use in a method described herein; and pharmaceutical compositions comprising denosumab and/or a PD-1 inhibitor for use in a method described herein.

IPC Classes  ?

• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The disclosure relates to double halogenated phenylalanine derivatives, which can be radiolabeled with PET or SPECT radioisotopes, and their use in treating and/or imaging cancer.

IPC Classes  ?

• C07C 215/02 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton

Abstract

The invention relates to relates to a chemical epigenetic modifier (CEM) comprising compound 1 (AP1867) or a pharmaceutically acceptable salt thereof, a linker, and a chromatin regulatory protein ligand and compositions thereof. The invention also relates to methods for modulating expression of a gene comprising contacting a polynucleotide with a target gene sequence to a fusion protein comprising a FK506-binding protein (FKBP) polypeptide with a F36V mutation and a gRNA binding polypeptide, a gRNA comprising a gene targeting polynucleotide sequence that binds to a target gene sequence and a polynucleotide sequence recognized by the gRNA binding polypeptide, a CEM, and a protein with a DNA binding domain that binds to the target gene sequence and the gRNA, thereby modulating expression of the gene.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 31/44 - Non-condensed pyridinesHydrogenated derivatives thereof
• A61K 31/5517 - 1,4-Benzodiazepines, e.g. diazepam condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
• C07D 211/60 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• C07D 487/04 - Ortho-condensed systems
• C07D 495/14 - Ortho-condensed systems
• C12N 9/22 - Ribonucleases
• C12N 9/90 - Isomerases (5.)
• C12N 15/11 - DNA or RNA fragmentsModified forms thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

A method for automated assessment of aseptic technique of compounding in a compounding hood includes collecting, using sensors positioned in or around a compounding hood, data from which positions, orientations, and movements of objects used in an aseptic compounding task can be determined. The method further includes feeding the data into an automated aseptic technique evaluator. The method further includes identifying, using the automated aseptic technique evaluator and from the data, phases of the aseptic compounding task. The method further includes automatically detecting, by the automated aseptic technique evaluator, errors occurring during at least some of the phases. The method further includes generating and displaying, by the automated aseptic technique evaluator, output indicative of the errors.

IPC Classes  ?

• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
• G16C 20/70 - Machine learning, data mining or chemometrics

Abstract

Described herein are compounds for modifying meiotic recombination in a plant. In addition, described herein are methods of modifying meiotic recombination in a plant, including methods that can reduce linkage drag in a plant, increase recombination in a cold region of the genome of a plant, and/or reduce the number of backcross generations in a plant breeding method.

IPC Classes  ?

• A01H 1/06 - Processes for producing mutations, e.g. treatment with chemicals or with radiation

Abstract

The invention relates to modified chimeric AAV capsids, virus vectors comprising the same, and methods of using the vectors such as to target the lung. The invention further relates to modified chimeric AAV capsids with improved infectivity to a lung cells, virus vectors comprising the same, and methods of using the vectors to target lung cells with improved infectivity.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors

Abstract

The invention relates to modified chimeric AAV capsids, virus vectors comprising the same, and methods of using the vectors such as to target the nervous system. The invention further relates to modified chimeric AAV capsids with improved infectivity to neural cells, virus vectors comprising the same, and methods of using the vectors to target neural cells with improved infectivity.

IPC Classes  ?

• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

This invention relates to human papilloma virus (HPV) positive cancers such as HPV+ squamous cell carcinoma of the oropharynx (OPSCC). This invention further relates methods of determining treatment regimens, methods of stratifying prognosis from treatment of HPV positive cancers, methods of determining suitability for de-escalation of treatment of HPV positive cancers, and methods of treating HPV positive cancers.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving virus or bacteriophage

Abstract

Described herein are compositions, devices, and methods for improving a surface property of a substrate. In some embodiments, the hydrophobicity and/or fluorocarbon-phobicity of the surface is increased. Some embodiments include compositions, devices and methods for improving bead loading and/or immiscible oil sealing of microwell array reactions on plastic microfluidic devices.

IPC Classes  ?

• C09D 183/08 - Polysiloxanes containing silicon bound to organic groups containing atoms other than carbon, hydrogen, and oxygen
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C09D 5/00 - Coating compositions, e.g. paints, varnishes or lacquers, characterised by their physical nature or the effects producedFilling pastes
• C09D 7/20 - Diluents or solvents

Abstract

Modular active surface devices for microfluidic systems and methods of making same is disclosed. In one example, the modular active surface device includes an active surface layer mounted atop an active surface substrate, a mask mounted atop the active surface layer wherein the mask defines the area, height, and volume of the reaction chamber, and a substrate mounted atop the mask wherein the substrate provides the facing surface to the active surface layer. In other examples, both facing surfaces of the reaction chamber include active surface layers. Further, the modular active surface device can include other layers, such as, but not limited to, adhesive layers, stiffening layers for facilitating handling, and peel-off sealing layers. Further, a large-scale manufacturing method is provided of mass producing the modular active surface devices. Further, a method is provided of using a plasma bonding process to bond the active surface layer to the active surface substrate.

IPC Classes  ?

• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention provides a chimeric antigen receptor (CAR) that recognizes CSPG4 as well as methods of use in the treatment of diseases and disorders.

IPC Classes  ?

• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• A61K 40/11 - T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cellsLymphokine-activated killer [LAK] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61K 40/42 - Cancer antigens
• C07K 14/725 - T-cell receptors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

in vivoin vivo transduction.

IPC Classes  ?

• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C12N 15/86 - Viral vectors
• C12N 5/0781 - B cellsProgenitors thereof

Abstract

Arylbenzoisoxazole compounds of Formula II, where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cancer, and viral infections. Methods of using compounds of Formula II for prevention or treatment of such diseases and disorders, pharmaceutical compositions comprising the compounds, and methods of preparing the compounds are also disclosed. Arylbenzoisoxazole compounds of Formula II, where R1 and R2 are defined herein, are useful for inhibiting isoforms of IP6K and IPMK, and for treating diseases and disorders such as non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cancer, and viral infections. Methods of using compounds of Formula II for prevention or treatment of such diseases and disorders, pharmaceutical compositions comprising the compounds, and methods of preparing the compounds are also disclosed.

IPC Classes  ?

• C07D 261/20 - Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61K 31/4245 - Oxadiazoles
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/10 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention provides methods and compositions comprising an adeno-associated virus (AAV) capsid protein, comprising one or more amino acids substitutions, wherein the substitutions introduce a new glycan binding site into the AAV capsid protein.

IPC Classes  ?

• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• C07K 14/075 - Adenoviridae
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/86 - Viral vectors
• C12N 15/861 - Adenoviral vectors

Abstract

Composite particle including the following: (1) a nanocrystal of an organic compound, and (2) a block copolymer associated with one or more surfaces of the nanocrystal of an organic compound. The organic compound, in some embodiments, is a pharmaceutical compound, a therapeutic compound, and/or a bioactive compound. The block copolymer may be a block copolymer with at least one hydrophilic poly(2-oxazoline) block. Pharmaceutical compositions may include these composite particles. The pharmaceutical compositions may include a dispersion that has an aqueous or aqueous-based continuous phase and a dispersed phase that includes the composite particles. The dispersion may be administered to sick patients, including those diagnosed with or exhibiting symptoms of COVID-19. For example, the dispersion may be aerosolized, and a patient may inhale the aerosol.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 9/19 - Particulate form, e.g. powders lyophilised
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/4965 - Non-condensed pyrazines
• A61K 31/569 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. oestrane, oestradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone substituted in position 17 alpha, e.g. ethisterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61P 31/14 - Antivirals for RNA viruses

Abstract

Provided herein are antibodies and antibody fragments that bind to the S2 subunit of the SARS-CoV-2 spike protein. Methods of treating or preventing SARS-CoV-2 infections are provided, comprising administering to a patient in need thereof an effective amount of a SARS-CoV-2 spike protein S2 subunit-targeting antibody.

IPC Classes  ?

• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
• A61P 31/14 - Antivirals for RNA viruses
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Iodide nanoparticles are provided. The nanoparticles can be potassium iodide (KI) nanoparticles, and can be formed of, a radioisotope, preferably 131I or 125I. The nanoparticles can include a coating that can increase the half-life of the particles, serve as a platform for attachment or entrapment of targeting moieties and/or additional active agents, or a combination thereof. Methods of use are also provided. For example, a method of treating a subject for cancer can including sensitizing the subject to radiation therapy by administrating the iodide nanoparticles to the subject in combination with one or more doses of radiation therapy. Methods of treating or imaging a subject can also include administering the subject an effective amount iodide nanoparticles, without the nanoparticles serving as radiosensitizer. In such methods, the nanoparticles typically include a radioisotope or an anticancer active agent, for example 131I, 125I, 124I, or 123I, or a chemotherapeutic agent.

IPC Classes  ?

• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
• A61P 35/00 - Antineoplastic agents

Abstract

The present disclosure is directed to kappa opioid receptor ligands and pharmaceutical compositions thereof and their utility as anti-nociceptive agents. Specifically, the disclosed kappa opioid ligands are G-protein biased kappa opioid agonists containing a bis amide core.

IPC Classes  ?

• C07D 405/12 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 213/81 - AmidesImides
• C07D 213/82 - AmidesImides in position 3
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 409/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/443 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/36 - Opioid-abuse

Abstract

Methods of treating neurodegenerative disorders, including Alzheimer's disease, are provided. Such methods include administering a therapeutically effective amount of a G9a-interacting small molecule therapeutic to a subject suffering from a neurodegenerative disorder. The G9a-interacting small molecule therapeutic includes MS1262.

IPC Classes  ?

• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61K 31/13 - Amines, e.g. amantadine
• A61K 31/33 - Heterocyclic compounds

Abstract

The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that may introduce a domain and/or an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

This invention relates to methods and compositions for inhibiting fibrosis and the formation of scars, e.g., as a result of corneal wounds, by administering NBL1 to a subject. The invention further relates to methods and compositions for inhibiting the growth of developing scars by administering NBL1 to the scar. The invention also relates to methods and compositions for facilitating wound re-epithelialization and partially restoring corneal stromal thickness by administering NBL1 to the wounded cornea.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Disclosed herein are modified NKTs expressing human IL-12, compositions comprising the modified NKTs, and therapeutic methods for using the modified NKTs. The modified NKTs described herein are reprogrammed NKTs that demonstrate long term persistence when the expression of IL-12 is coupled with the expression of a CAR. These NKTs acquire long-term capacity to eliminate tumor cells and long-term persistence of NKTs expressing IL-12. Also disclosed herein are modified cells transformed to express a CAR and an exogenous membrane-bound moiety, such as IL-12.

IPC Classes  ?

• A61K 40/42 - Cancer antigens
• A61K 38/20 - Interleukins
• A61K 40/15 - Natural-killer [NK] cellsNatural-killer T [NKT] cells
• A61K 40/31 - Chimeric antigen receptors [CAR]
• A61P 35/00 - Antineoplastic agents
• C07K 14/54 - Interleukins [IL]
• C07K 14/725 - T-cell receptors
• C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
• C12N 15/86 - Viral vectors

Abstract

Carbon is one of the most common elements in bioactive organic compounds. Theoretically, nearly all carbon-based organic functional groups can be labeled with 11C if an appropriate 11C-synthon is developed and utilized. Although there are various reports on developing PET agents based on alkyl [11C]nitriles, efficient and facile cyanation of arenes with radioisotope-containing reagents, particularly electron-rich arenes, still requires further improvements. The organic photoredox-catalyzed cyanation method reported herein introduces a [11C]nitrile quickly with high radiochemical conversion (RCC) in a metal-free manner, which can also be further diversified to other functional groups such as [11C]carboxylic acids, [11C]amides, and [11C]alkyl amines.

IPC Classes  ?

• C07C 253/30 - Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/16 - Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes

Abstract

This invention relates to polynucleotides comprising optimized CLN5 open reading frame (ORF) sequences, vectors comprising the same, and methods of using the same for delivery of the ORF to a cell or a subject and to treat disorders associated with aberrant expression of a CLN5 gene or aberrant activity of a CLN5 gene product in the subject, such as CLN5 disease.

IPC Classes  ?

• C12N 15/86 - Viral vectors
• A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

This invention relates to recombinant aptamer 9.3t-resistant Factor IX proteins, as well as methods of making the same and methods of using the same in methods comprising non-hemophilic subjects, including methods of modeling Factor IX replacement therapy in a non-hemophilic subject and methods of identifying genetic background effects of a non-hemophilic subject on an exogenous Factor IX replacement protein. The invention also pertains to methods of modeling gene and/or protein replacement therapy in a protein non-deficient subject and methods of identifying genetic background effects of a protein non-deficient subject on an exogenous replacement protein, as well as methods of selecting aptamer-resistant recombinant proteins and selecting aptamer-sensitive protein non-deficient subjects for use in such methods as disclosed herein.

IPC Classes  ?

• C12N 9/64 - Proteinases derived from animal tissue, e.g. rennin
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 49/00 - Preparations for testing in vivo
• G01N 33/86 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving blood coagulating time

Abstract

This invention relates synthetic modified polypeptides which bind to the Orai1 calcium channel, and their therapeutic use in disorders such as, but not limited to, disorders of the respiratory system.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
• A61K 31/431 - Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula , e.g. penicillins, penems containing further heterocyclic ring systems, e.g. ticarcillin, azlocillin, oxacillin
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
• A61K 31/7036 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 38/08 - Peptides having 5 to 11 amino acids
• A61K 38/14 - Peptides containing saccharide radicalsDerivatives thereof
• A61P 11/00 - Drugs for disorders of the respiratory system

Abstract

In one aspect, composite exosomal compositions are described herein employing a linker for coupling small molecules to the exosome. In some embodiments, a composite composition comprises an exosome, and at least one small molecule coupled or attached to the exosome via a linker, the linker at least partially disposed in the exosomal membrane.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 1/00 - Microorganisms, e.g. protozoaCompositions thereofProcesses of propagating, maintaining or preserving microorganisms or compositions thereofProcesses of preparing or isolating a composition containing a microorganismCulture media therefor
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances

Abstract

Chlamydia trachomatisChlamydia trachomatis infection. In addition, the composition may further include a TLR agonist and/or an oil-in-water emulsion so as to increase the efficacy of the CPAF immunogen. This invention also describes methods of administration of the composition, including mucosal administration.

IPC Classes  ?

• A61K 39/118 - Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61P 31/04 - Antibacterial agents
• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

Provided are chlamydial protease-like activity factor (CPAF) polypeptides conjugated to an adjuvant, such as through click chemistry, and uses thereof. Uses include as vaccines for protection against chlamydia infections.

IPC Classes  ?

• C07K 14/295 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Chlamydiales (O)
• A61K 39/118 - Chlamydiaceae, e.g. Chlamydia trachomatis or Chlamydia psittaci
• A61P 31/04 - Antibacterial agents
• A61P 37/04 - Immunostimulants
• C07K 19/00 - Hybrid peptides

Abstract

Electrically conductive membranes (ECMs) have been demonstrated in the literature as a promising tool to enhance the performance of membrane-based water/wastewater treatment technologies. Membrane surface functionalization with “active” conductive materials is a direct and effective approach to obtain membranes with electrically conductive properties. However, a general strategy that could be utilized to fabricate ECMs using any types of commercial membrane (e.g., reverse osmosis, nanofiltration, ultrafiltration, and microfiltration) as a support or any type of conductive material as ‘active material’ is not available yet. To address this need, the subject matter described herein is a facile and low-cost polyethyleneimine/glutaraldehayde-based method for synthesis of electrically conductive membranes starting from a broad range of commercial membranes (i.e., SWC4+, ESPA3, NF 270, PSf 20 KDa, and 0.1 μm PVDF membranes) by using graphite or other conductive materials, including but not limited to, carbon nanotubes, activated charcoal, reduced graphene oxide, and silver nanoparticles.

IPC Classes  ?

• B01D 69/10 - Supported membranesMembrane supports
• B01D 65/08 - Prevention of membrane fouling or of concentration polarisation
• B01D 67/00 - Processes specially adapted for manufacturing semi-permeable membranes for separation processes or apparatus
• B01D 71/02 - Inorganic material
• B01D 71/60 - Polyamines

Abstract

Described herein are surface treatment methods for removing one or more surface defect layers from polycrystalline films, polycrystalline films that are free of one or more defect surface layers, and use of the films in solar cells. In certain embodiments, the method is conducted by means of an adhesive tape or mechanical polishing. As described herein, solar cells containing the surface treated perovskite films show enhanced efficiency and stability.

IPC Classes  ?

• H10K 71/20 - Changing the shape of the active layer in the devices, e.g. patterning
• B08B 7/00 - Cleaning by methods not provided for in a single other subclass or a single group in this subclass
• C07F 7/24 - Lead compounds
• C07F 19/00 - Metal compounds according to more than one of main groups
• H10K 30/40 - Organic devices sensitive to infrared radiation, light, electromagnetic radiation of shorter wavelength or corpuscular radiation comprising a p-i-n structure, e.g. having a perovskite absorber between p-type and n-type charge transport layers
• H10K 30/50 - Photovoltaic [PV] devices
• H10K 85/50 - Organic perovskitesHybrid organic-inorganic perovskites [HOIP], e.g. CH3NH3PbI3

Abstract

The present invention provides methods of treating an autoimmune disorder comprising administering to the subject an effective amount of a molecule comprising molecules having multispecificity, such as wherein at least one of a first immunoglobulin fragment antigen binding region (Fab1) and at least one of a second immunoglobulin fragment antigen binding region (Fab2), wherein Fab1 is specific for FcγRI or FcγRIIa, and wherein Fab2 is specific for FcγRIIb.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Methods and systems for automating injection in a laboratory. In some examples, a method includes obtaining, using a robotic arm attached to a mobile robotic base, a sample through an injection tool. The method includes navigating the mobile robotic base to laboratory apparatus having an injection port. The method includes computing, using a sensor system configured to detect the injection tool, a motion path for the robotic arm to align the injection tool with the injection port. The method includes moving, using the motion path, the robotic arm such that a tip of the injection tool enters the injection port.

IPC Classes  ?

• B25J 5/00 - Manipulators mounted on wheels or on carriages
• B25J 13/00 - Controls for manipulators
• A61B 5/153 - Devices for taking samples of blood specially adapted for taking samples of venous or arterial blood, e.g. by syringes
• B25J 11/00 - Manipulators not otherwise provided for
• B25J 9/16 - Programme controls
• B25J 19/02 - Sensing devices

Abstract

The invention relates to synthetic liver-specific promoters and expression constructs for producing polypeptides and functional nucleic acids in the liver of a subject. The invention further relates to Factor VIII proteins containing modifications in the amino acid sequence of the Factor VIII protein, as well as nucleic acid constructs encoding the Factor VIII proteins and methods of using these compositions to treat a bleeding disorder.

IPC Classes  ?

• C07K 14/755 - Factors VIII
• A61K 38/00 - Medicinal preparations containing peptides
• C12N 15/63 - Introduction of foreign genetic material using vectorsVectorsUse of hosts thereforRegulation of expression
• C12P 21/02 - Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione

Abstract

A method for estimating gestational age of a human fetus using a trained machine learning model with an attention function includes receiving, at a feature extraction module of a trained machine learning model, fetal ultrasound image data for at least one image of a human fetus, and producing, by propagating the ultrasound image data through the feature extraction module, at least one feature vector from the ultrasound image data. The method further includes providing the at least one feature vector as input to an attention module of the trained machine learning model and producing, by propagating the feature vectors through the attention module, a weighted sum vector that aggregates and weights the feature vectors. The method further includes providing the weighted sum vector as input to a gestational age prediction module of the trained machine learning model, which generates, from the weighted sum vector, an estimate of the gestational age of the human fetus. The method further includes outputting the estimate of gestational age to a user.

IPC Classes  ?

• A61B 8/08 - Clinical applications
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves
• G06N 3/0464 - Convolutional networks [CNN, ConvNet]

Goods & Services

Business networking, namely, providing business mentoring in the nature of advice in the fields of innovation and entrepreneurship; Business development services, namely, business consultation and advisory services; providing business incubator facilities, namely, rental of office equipment and machinery as well as providing business advisory services; all of the foregoing for start-up, re-start and spin-out companies; Business development services, namely, providing start-up support for the businesses of others; Business incubator services, namely, business management and business development services in the form of start-up support for the businesses of others; Business collaboration services, namely, providing a national computer-based networking web site for faculty and students for the purpose of promoting collaboration to accelerate the development and deployment of advanced manufacturing and new products in the arts and other fields; Business collaboration services, namely, promoting the creation of physical objects and prototyping for education, research, entrepreneurship and recreation; Market analysis; providing economic impact analysis services in the field of IP-based startups, namely, tracking and reporting on IP-based startups on social ventures, managing a database that tracks and generates reports on IP-based startups and social ventures, and the economic impact of such startups in North Carolina Fundraising services by means of organizing, arranging and conducting fundraising programs, for promoting research, education and other activities relating to innovation and entrepreneurship; charitable fundraising services for promoting innovation, new ideas and innovative technology; Fundraising services, namely, providing financial assistance for programs and services of others; providing fundraising activities to support innovation, new ideas, innovative technology and entrepreneurship; Providing grants for innovation, new ideas, innovative technology and entrepreneurship; providing technology development grants to aid in the advancement of developing unlicensed technologies to a commercial endpoint; providing technology development grants to help establish applications and proof-of-concept, prototype development, technology validation and intellectual property assistance; providing financial kick starter awards for start-ups in the fields of life sciences and technologies; Providing incubation services for business, namely, leasing of office space and facilities; financial risk assessment services that enables inventors to assess technology, marketplace and investment funding, and assist in increasing the creation of IP-based technology startups in North Carolina Educational services, conducting seminars and educational events relating to promoting innovation, new ideas and innovative technology; Education and training services, namely, organization, arranging and conducting of workshops, colloquiums, conferences, congresses, courses, seminars, training courses, symposiums in the field(s) of innovation and entrepreneurship; educational services, namely, providing a learning and innovation center featuring leadership, motivational, educational, and brainstorming training; leadership development training in the fields of innovation and entrepreneurship; providing group coaching and in-person learning forums in the field of leadership development in innovation and entrepreneurship; Educational and entertainment services, namely, arranging and conducting summits, conferences, seminars, workshops, case study presentations, panel discussions, and roundtable forums in the field of business strategy, data, innovation, and entrepreneurship, bringing together academia and industry leaders to enable the exchange of ideas, strategies, tactics, and best practices in the field of business strategy, data, innovation, and entrepreneurship; Educational services, namely, arranging and conducting educational conferences, meetings, roundtable discussion groups and summits in the nature of think tank activities for the purposes of generating thought-provoking ideas, concepts and recommendations related to the application of technology, innovation, and entrepreneurship; educational services, namely, providing mentoring services in the field of business; educational services, namely, providing mentoring services in the field of business, namely, innovation, and entrepreneurship; educational services, namely providing mentoring services to the membership of a collaborative community in the field of start up, re-start and spin-out companies

Abstract

A stamp-transfer method for deposition of DNA, protein-DNA complexes, other polymers, and other biomolecules for scanning probe microscopy, including atomic force microscopy (AFM) as well as other imaging techniques. The method is suitable for adaptation to high-throughput depositions and can improve image resolution of the conformational states of protein-DNA complexes.

IPC Classes  ?

• G01N 35/10 - Devices for transferring samples to, in, or from, the analysis apparatus, e.g. suction devices, injection devices
• G01N 35/00 - Automatic analysis not limited to methods or materials provided for in any single one of groups Handling materials therefor

Abstract

The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating virus infection in the respiratory tract and virus transmission through the respiratory tract. In particular, the presently-disclosed subject matter relates to inhibiting and treating virus infection in a subject using compositions and antibodies that trap viruses in mucus of the respiratory tract, thereby inhibiting transport of virus across or through mucus secretions.

IPC Classes  ?

• A61K 39/42 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum viral
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 31/12 - Antivirals
• C07K 16/10 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses

Abstract

The current invention relates to nuclear receptor-binding SET domain-containing 2 (NSD2)-targeted protein degradation reagents and pharmaceutical compositions thereof and their utility as anti-cancer agents.

IPC Classes  ?

• C07D 417/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
• C07D 265/36 - 1,4-OxazinesHydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
• C07D 413/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

The present invention relates to compositions and methods configured to deliver a stimulus (e.g., a therapeutic agent or a therapeutically beneficial signal) to a cell, tissue, organ, or organism. The stimulus is applied at least twice, and the first and second applications are separated by a rest period in which no further stimulus is actively applied. The rest period is of a duration (e.g., about 1-6 hours) sufficient to provoke an enhanced response to the second stimulus.

IPC Classes  ?

• A61N 2/02 - Magnetotherapy using magnetic fields produced by coils, including single turn loops or electromagnets
• A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular wayAccessories therefor, e.g. filling or cleaning devices, arm rests
• A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
• A61N 1/05 - Electrodes for implantation or insertion into the body, e.g. heart electrode
• A61N 1/32 - Applying electric currents by contact electrodes alternating or intermittent currents
• A61N 2/00 - Magnetotherapy
• A61N 5/06 - Radiation therapy using light
• C12N 13/00 - Treatment of microorganisms or enzymes with electrical or wave energy, e.g. magnetism, sonic waves

Abstract

A catheter-implemented transducer device for intravascular thrombolysis, is described herein. Such a transducer device includes a catheter defining a longitudinal axis and having opposed proximal and distal ends. At least one ultrasonic transducer arrangement is disposed about the distal end. The ultrasonic transducer arrangement is oriented with acoustic waves propagating parallel or perpendicular to the longitudinal axis. Optionally, the ultrasonic transducer arrangement is configured as a multi-layer stacked structure of ultrasonic transducer elements. Optionally, the ultrasonic transducer arrangement is a laser ultrasonic transducer arrangement. Optionally, the ultrasonic transducer arrangement is configured to operate in a lateral mode.

IPC Classes  ?

• A61B 17/22 - Implements for squeezing-off ulcers or the like on inner organs of the bodyImplements for scraping-out cavities of body organs, e.g. bonesSurgical instruments, devices or methods for invasive removal or destruction of calculus using mechanical vibrationsSurgical instruments, devices or methods for removing obstructions in blood vessels, not otherwise provided for
• A61B 18/00 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
• A61B 18/22 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor
• A61B 18/26 - Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibreHand-pieces therefor for producing a shock wave, e.g. laser lithotripsy

Abstract

Provided are methods for identifying pancreatic cancer subtypes in a subject and treating the same. In some embodiments, the method comprise obtaining gene expression levels for each of the following genes in the biological sample: GPR87, KRT6A, BCAR3, PTGES, ITGA3, C16orf74, S100A2, KRTS, REG4, ANXA10, GATA6, CLDN18, LGALS4, DDC, SLC40A1, CLRN3; performing pair-wise comparisons of gene expression levels for combinations of these genes; and calculating a Raw Score for the biological sample, wherein the Raw Score is indicative of the pancreatic cancer subtype in the subject. Also provided are methods for identifying differential treatment strategies for subjects diagnosed with PDAC, methods for treating PDAC patients based on the subtype of PDAC the patients have; and methods for classifying subjects diagnosed with PDAC as having a basal-like subtype or a classical subtype of PDAC.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G16B 25/00 - ICT specially adapted for hybridisationICT specially adapted for gene or protein expression
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation

Abstract

The present invention relates, in part, to methods, compounds, and compositions of an autophagy pathway inhibitor in combination with a dual RAF/MEK inhibitor, for treating abnormal cell growth (e.g., cancer).

IPC Classes  ?

• A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• A61P 35/00 - Antineoplastic agents

Abstract

A method for non-invasively evaluating quality of stored blood using acoustic radiation force impulse (ARFI) ultrasound includes placing a container of stored blood within an imaging region of an ultrasound transducer. The method further includes applying, using the ultrasound transducer, at least one ARFI pulse to mechanically displace the stored blood within the container and determine at least one measurement of displacement of the stored blood within the container. The method further includes determining, using the at least one measurement of displacement an indication of the quality of the stored blood within the container. The method further includes outputting the indication of the quality of the stored blood within the container.

IPC Classes  ?

• G01S 7/52 - Details of systems according to groups , , of systems according to group
• A61B 8/08 - Clinical applications
• G01N 29/02 - Analysing fluids
• G01N 29/34 - Generating the ultrasonic, sonic or infrasonic waves
• G01N 29/44 - Processing the detected response signal
• A61B 5/15 - Devices for taking samples of blood

Abstract

The present invention relates to labeled compounds suitable for positron emission tomography (PET) imaging and/or fluorescence imaging such as near-infrared fluorescence imaging (NIRF). The invention further relates to the use of these compounds for carrying out PET scans. imaging calcium sensing receptor (CSR)-positive organs. excising parathyroid tissue. protecting parathyroid tissue during thyroid surgery, and treating disorder(s) of a CSR-positive tissue in a subject.

IPC Classes  ?

• A61K 51/04 - Organic compounds

Abstract

Provided is a bioelectrochemical sensor for measuring a target substance which at least comprises: a working electrode which comprises a biosensing molecule, which can catalyze or bind to the target substance, and a reference electrode which comprises a bioreference molecule which harbors a redox species which can be electrochemically accessible to the reference electrode, thereby giving a specific redox potential but lacks a catalytic activity or binding ability to the target substance.

IPC Classes  ?

• A61B 5/1468 - Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value using chemical or electrochemical methods, e.g. by polarographic means
• G01N 27/327 - Biochemical electrodes
• G01N 30/96 - Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography using ion-exchange
• A61B 5/05 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

Arylbenzoisoxazole compounds of Formula I, where R1and R2are defined herein, are useful for degrading isoforms of IP6K and IPMK, and for treating diseases and disorders such as non- alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), cancer, and viral infections. Methods of using compounds of Formula I for prevention or treatment of such diseases and disorders, pharmaceutical compositions comprising the compounds, and methods of preparing the compounds are also disclosed.

IPC Classes  ?

• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• A61P 3/04 - AnorexiantsAntiobesity agents
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 31/10 - Antimycotics
• A61P 35/00 - Antineoplastic agents
• A61P 31/12 - Antivirals

Abstract

A method for evaluating respiratory function or structure of a subject includes providing a mixture including a liquid and ultrasound contrast agent particles, each of the inhalable ultrasound contrast agent particles comprising a core, a shell surrounding the core, and a mucus-targeting material in or on the shell, wherein the mucus-targeting comprises a material that binds with or adheres to respiratory mucus. The method further includes nebulizing the mixture to make the ultrasound contrast agent particles inhalable. The method further includes allowing a subject to inhale the nebulized mixture. The method further includes applying ultrasound energy to image the ultrasound contrast agent particles within the subject. The method further includes using results of the imaging to evaluate respiratory function or structure of the subject.

IPC Classes  ?

• A61K 49/22 - Echographic preparationsUltrasound imaging preparations
• A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites

Abstract

Catalytic carbonylation method using catalyst systems having a ligand salt which is a precursor to a carbene ligand and a transition metal compound.

IPC Classes  ?

• B01J 31/02 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
• B01J 31/22 - Organic complexes
• C07C 67/00 - Preparation of carboxylic acid esters

Abstract

Provided are pharmaceutical compositions for treating cancer patients. The pharmaceutical compositions include a combination of compounds inhibiting PTP1 b activity and chemotherapeutic agents. The PTP 1 b inhibitors in such pharmaceutical compositions can include a small molecule such as an anti-sense inhibitor, an allosteric/reversible inhibitor, and/or a permanent/chemical modification inhibitor. Methods of treating subjects are also provided. Such treatment methods include administering to a subject in need of treatment a pharmaceutical composition including one or more compounds inhibiting PTP1b activity and one or more chemotherapeutic agents. Also provided herein are methods of restoring an anti-tumor immune response in a subject receiving chemotherapy, including administering to the subject a PTP 1 b inhibitor prior to, during and/or after receiving a chemotherapeutic agent, whereby an anti-tumor immune response in the subject is restored and/or enhanced.

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 33/243 - PlatinumCompounds thereof
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

Provided herein according to some embodiments are modified dengue virus E proteins, compositions comprising the modified dengue virus E proteins, and methods of use. The modified dengue virus E protein comprise three or more amino acid substitutions that enable a tetravalent mixture of DENV1, DENV2, DENV3, and DENV4 serotypes without formation of E protein heterodimers that lower immunogenic efficacy of the E proteins.

IPC Classes  ?

• C07K 14/18 - Togaviridae, e.g. flavivirus, pestivirus, yellow fever virus, hepatitis C virus, japanese encephalitis virus
• A61K 38/02 - Peptides of undefined number of amino acidsDerivatives thereof
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• C12N 7/01 - Viruses, e.g. bacteriophages, modified by introduction of foreign genetic material
• C12N 15/40 - Proteins from RNA viruses, e.g. flaviviruses

Abstract

The present invention relates to ligands for M-phase phosphoprotein (MPP8) and pharmaceutical compositions thereof and their utility as anti-cancer agents.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• C07D 403/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 239/95 - QuinazolinesHydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
• C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 491/048 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
• A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
• A61P 35/00 - Antineoplastic agents

Abstract

Described is small molecule N-(l-isopropylpiperidin-4-yl)-6-methoxy-2-morpholino-7- (3-(pyrrolidin-l-yl)propoxy)quinolin-4-amine)) (MS 1262) that inhibits methyltransferases G9a/GLP. This inhibitor can be used for the treatment of patients with G9a/GLP related diseases such as Alzheimer's Disease and Prader-Willi Syndrome.

IPC Classes  ?

• A61K 31/4706 - 4-Aminoquinolines8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/47 - QuinolinesIsoquinolines
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/5375 - 1,4-Oxazines, e.g. morpholine
• A61K 31/535 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
• A61K 31/33 - Heterocyclic compounds